Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash

Group 1 - Janux Therapeutics (NASDAQ: JANX) has garnered significant interest from investors, alongside various buy-out rumors [1] - The company specializes in the research and development of novel Cell & Gene Therapies (CGT) aimed at addressing multiple clinical needs [1] - The analysis will focus on biotechnology, pharmaceutical, Medtech, and healthcare stocks, leveraging expertise in life sciences to evaluate the potential of new treatments [1]